Reports Q4 revenue $1.867M, consensus $2.09M. “We entered 2026 with two strategic growth drivers,” said Ofer Gonen, Chief Executive Officer of MediWound (MDWD). “Our Phase III VALUE trial of EscharEx continues to progress as planned, with key clinical milestones, including interim assessment and enrollment completion, anticipated by year-end. In parallel, our expanded NexoBrid manufacturing facility is now operational, positioning us to support global demand following regulatory approvals. With these value-creating catalysts, a strong balance sheet, and an experienced team, MediWound is now well-positioned to advance into a new phase of scale and commercial readiness.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDWD:
- MediWound management to meet with Maxim
- Is MDWD a Buy, Before Earnings?
- MediWound Shareholders Approve Expansion of 2024 Equity Incentive Pool
- MediWound Calls February 19, 2026 Extraordinary Meeting to Expand 2024 Share Incentive Plan
- Mediwound: NexoBrid Capacity Expansion and EscharEx Pipeline Catalysts Support Buy Rating and $36 Target